http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111407764-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-585 |
filingDate | 2020-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2021-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2021-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-111407764-B |
titleOfInvention | Application of heteroterpene derivative in preparation of medicine for resisting non-alcoholic steatohepatitis and hepatic fibrosis |
abstract | The invention discloses an application of a novel skeleton heteroterpene derivative in preparing a medicine for resisting non-alcoholic steatohepatitis and hepatic fibrosis, wherein the structural formula of the novel skeleton heteroterpene derivative is shown as a formula (I): the novel framework heteroterpene derivative can remarkably reduce the expression level of alpha-SMA mRNA in HSC-T6 cells, remarkably inhibit the activity of alpha-SMA mRNA expression induced by TGF-beta 1, has the action effect equivalent to that of a positive medicament luteolin, and has no cytotoxicity and high safety factor under the action concentration; therefore, the novel skeleton heteroterpene derivative has good application prospect in preparing medicines for resisting non-alcoholic steatohepatitis and hepatic fibrosis. |
priorityDate | 2020-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 194.